Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2016, and provided an update on the Company’s clinical development programs and regulatory outlook for the remainder of 2016.

“We are pleased to have completed the submission of our NDA for rucaparib in the treatment of advanced ovarian cancer in late June,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “We continue to focus on our broader clinical development program for rucaparib, and are actively preparing for a potential U.S. launch of rucaparib.”
MORE ON THIS TOPIC